TScan Therapeutics, Inc. (NASDAQ:TCRX) Sees Large Drop in Short Interest

TScan Therapeutics, Inc. (NASDAQ:TCRX) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 2,000,000 shares, a decline of 20.6% from the December 31st total of 2,520,000 shares. Based on an average trading volume of 403,800 shares, the short-interest ratio is currently 5.0 days. Approximately 4.6% of the company’s shares are sold short.

Analysts Set New Price Targets

A number of research firms have recently commented on TCRX. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a report on Wednesday, December 11th. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of TScan Therapeutics in a report on Wednesday, December 11th. Finally, Wedbush restated an “outperform” rating and set a $7.00 price objective on shares of TScan Therapeutics in a report on Monday, December 23rd.

TScan Therapeutics Stock Down 5.4 %

Shares of TCRX stock traded down $0.14 during trading hours on Monday, hitting $2.43. 301,477 shares of the company were exchanged, compared to its average volume of 294,022. The stock has a market capitalization of $129.69 million, a price-to-earnings ratio of -2.29 and a beta of 0.88. TScan Therapeutics has a one year low of $2.31 and a one year high of $9.69. The business’s 50-day simple moving average is $3.20 and its two-hundred day simple moving average is $4.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.86 million. Sell-side analysts predict that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TCRX. China Universal Asset Management Co. Ltd. bought a new stake in TScan Therapeutics during the fourth quarter worth approximately $32,000. Heck Capital Advisors LLC acquired a new position in TScan Therapeutics in the 4th quarter worth approximately $61,000. SG Americas Securities LLC boosted its stake in TScan Therapeutics by 31.2% in the 4th quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock worth $62,000 after purchasing an additional 4,852 shares during the period. Dimensional Fund Advisors LP acquired a new position in TScan Therapeutics in the 2nd quarter worth approximately $70,000. Finally, The Manufacturers Life Insurance Company acquired a new position in TScan Therapeutics in the 2nd quarter worth approximately $90,000. 82.83% of the stock is currently owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.